BCA
SRPT icon

Bay Colony Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Bay Colony Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,107
Closed -$230K – 223
2018
Q4 		$230K Sell
2,107
-2,800
-57% -$350K 0.2% 134
2018
Q3 		$793K Buy
4,907
+3,507
+251% +$479K 0.61% 43
2018
Q2 		$185K Buy
+1,400
New +$132K 0.13% 166

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bay Colony Advisors's SRPT Position: Q1 2019 in Review

Bay Colony Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2019, closing a stake of 2,107 shares — an estimated $230K sold.

Bay Colony Advisors first reported a position in SRPT in Q2 2018 and held it in 3 quarters. The position peaked at $793K in Q3 2018. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

  • Bay Colony Advisors reported no remaining Sarepta Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Bay Colony Advisors sold 2,107 Sarepta Therapeutics shares in Q1 2019, an estimated $230K.
  • Bay Colony Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 3 quarters.
  • Bay Colony Advisors's Sarepta Therapeutics position peaked at $793K in Q3 2018.
  • 371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on Bay Colony Advisors's 13F filing for Q1 2019, filed 30 Apr 2019.